Literature DB >> 30481156

Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome.

Hanneke J B H Beijers1,2, Nike M L Stikkelbroeck2, Arjen R Mensenkamp3, Rolph Pfundt3, Rob B van der Luijt4, Henri J L M Timmers2, Ad R M M Hermus2, Marlies J E Kempers3.   

Abstract

Context Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease caused by mutations in the tumor suppressor gene MEN1 and can be diagnosed based on clinical, familial and/or genetic criteria. We present a family in which we found both germline and somatic mosaicism for MEN1. Family description In our proband, we diagnosed MEN1. The mutation was not detected in her parents (DNA extracted from leucocytes). When her brother was found to harbor the same MEN1 mutation as our proband and, around the same time, their father was diagnosed with a neuroendocrine carcinoma, this tumor was investigated for the MEN1 mutation as well. In the histologic biopsy of this tumor, the same MEN1 mutation was detected as previously found in his children. Re-analysis of his blood using multiplex ligation-dependent probe amplification (MLPA) showed a minimal, but consistently decreased signal for the MEN1-specific MLPA probes. The deletion was confirmed in his son by high-resolution array analysis. Based on the array data, we concluded that the deletion was limited to the MEN1 gene and that the father had both germline and somatic mosaicism for MEN1. Conclusions To our knowledge, this is the first reported family with combined germline and somatic mosaicism for MEN1. This study illustrates that germline mosaicism is important to consider in apparently sporadic de novo MEN1 mutations, because of its particular importance for genetic counseling, specifically when evaluating the risk for family members and when considering the possibility of somatic mosaicism in the parent with germline mosaicism.

Entities:  

Mesh:

Year:  2019        PMID: 30481156     DOI: 10.1530/EJE-18-0778

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  Systematic detection of mosaicism by using digital NGS reveals three new MEN1 mosaicisms.

Authors:  Arnaud Lagarde; Grégory Mougel; Lucie Coppin; Magalie Haissaguerre; Lauriane Le Collen; Amira Mohamed; Marc Klein; Marie-Françoise Odou; Antoine Tabarin; Hedia Brixi; Thomas Cuny; Brigitte Delemer; Anne Barlier; Pauline Romanet
Journal:  Endocr Connect       Date:  2022-10-14       Impact factor: 3.221

Review 2.  Genetic and Epigenetic Causes of Pituitary Adenomas.

Authors:  Mengqi Chang; Chengxian Yang; Xinjie Bao; Renzhi Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

3.  Multiple endocrine neoplasia type 1 combined with thyroid neoplasm: A case report and review of literatures.

Authors:  Jia-Lu Xu; Su Dong; Le-Le Sun; Jin-Xin Zhu; Jia Liu
Journal:  World J Clin Cases       Date:  2022-01-21       Impact factor: 1.337

4.  Multiple endocrine neoplasia type 1: a new germline "homozygous" variant (c.201delC) caused by detection errors.

Authors:  Fan Zhang; Xiaohui Yu; Xiaoli Wang; Hua Shao
Journal:  Hered Cancer Clin Pract       Date:  2022-03-07       Impact factor: 2.857

5.  Heterogeneity of the Clinical Presentation of the MEN1 LRG_509 c.781C>T (p.Leu261Phe) Variant Within a Three-Generation Family.

Authors:  Aleksandra Gilis-Januszewska; Anna Bogusławska; Kornelia Hasse-Lazar; Beata Jurecka-Lubieniecka; Barbara Jarząb; Anna Sowa-Staszczak; Marta Opalińska; Magdalena Godlewska; Anna Grochowska; Anna Skalniak; Alicja Hubalewska-Dydejczyk
Journal:  Genes (Basel)       Date:  2021-03-31       Impact factor: 4.096

Review 6.  Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.

Authors:  Vinaya Srirangam Nadhamuni; Márta Korbonits
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

Review 7.  Genetics of Acromegaly and Gigantism.

Authors:  Anna Bogusławska; Márta Korbonits
Journal:  J Clin Med       Date:  2021-03-29       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.